Search academic texts

Information × Registration Number 0220U101037, 0118U001713 , R & D reports Title To evaluate of risks of late oncological and somato-neurological effects from the treatment of thyroid cancer for the substantiation of clinical and methodological support of special therapy popup.stage_title Head Васильєв Л Я., Registration Date 31-01-2020 Organization State Organization "Grigoriev Institute for Medical Radiologiy of the National Academy of Medical Sciences of Ukraine" popup.description2 Оbject of study: refined estimates of the risk of developing long-term negative iatrogenic effects, depending on the scheme of treatment of the first tumor in thyroid cancer. The purpose of the study: is to provide a scientific justification for the program of accompanying therapy for the treatment of thyroid tumors to prevent the long-term negative effects of special treatment. Research methods: nonparametric statistics, technology of Data Mining. Theoretical results: it was shown that the onset of ablation exceeding 20 months from the start of radionuclide therapy (RT) and a necessity to increase the dose of thyroid hormone to get a suppressive state in patients to the level above 3 μg / kg are unfavorable factors for the emergence of oncological complications. Practical results: it was shown that even a slight increase in thyroglobulin level (from 1.7 ng / ml) in the suppression therapy requires additional methods of examination of patients. The necessity of using glucocorticoids as a standard element of concomitant therapy in RT has been proved. Novelty: It has been shown first that necessity to exceed the average therapeutic dose of thyroid hormone to get a suppressive state in patients, are unfavorable factors for the oncological complications. It has been substantiated first that the use of glucocorticoids as an element of concomitant therapy with RT plays a role as a preventing factor against the occurrence of oncological complications. It has been found first that even a slight increase in thyroglobulin level (from 1.7 ng / ml) during the suppressive therapy may be a cause for onset of oncological complications. It was estimated first that the special treatment increases the total number of cardiovascular complications – 1.7, of pathologies of the urinary system - 3.1, pathologies of the digestive system - 1.8 times. The effectiveness of implementation: 1 article and 2 abstracts. Field of use: nuclear medicine, radiology. Product Description popup.authors Vasyliev Leonid Ya. Danilchenko Iryna O. Kulinich Halyna V. Lukhovytska Nataliia I. Myrna Olha M. Pidchenko Nataliia S. Radzishevska Yevheniia B. Savchenko Antonina S. Solodovnikova Olena O. popup.nrat_date 2020-04-02 Close